{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:13:39Z","timestamp":1794716019963,"version":"4.9.1"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,2,6]],"date-time":"2009-02-06T00:00:00Z","timestamp":1233878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The recent approval of bortezomib for the treatment of mantle cell lymphoma (MCL) by the US Food and Drug Administration is based on the results of the multicentre PINNACLE study with supportive data from a number of single and multicentre Phase 2 studies. This multicentre Phase 2 study enroled 40 patients with heavily pretreated MCL. The overall response rate (ORR) was 47%, including 5 complete remissions and 14 partial remissions. Overall, these remissions are relatively durable. The ORR in relapsed and refractory patients was 50% and 43% respectively (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b774), while both populations of patients exhibited essentially similar progression\u2010free survival (PFS; 5\u00b76\u2003months vs. 3\u00b79\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b781). Responding patients experienced a PFS from bortezomib that was similar to their line of prior therapy (7\u00b78\u2003months vs. 8\u00b74\u2003months, respectively). The data showed similar responses in relapsed and refractory patients as well as remission durations similar to prior therapy, suggesting that there may be little cross\u2010resistance with other conventional cytotoxic agents. Importantly, these data suggest that MCL patients with refractory or poorly responsive disease may still derive meaningful clinical benefit from treatment with bortezomib.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07466.x","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T05:04:08Z","timestamp":1233983048000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Patients with chemotherapy\u2010refractory mantle cell lymphoma experience high response rates and identical progression\u2010free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial"],"prefix":"10.1111","volume":"145","author":[{"given":"Owen A.","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Portlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otilia","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Sarasohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Butos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Neylon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hamelers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mac\u2010Gregor Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Blumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Zelenetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl316"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62571-0"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2759.2759","article-title":"The schedule\u2010dependent combination of bortezomib with rituximab, cyclophosphamide and prednisone produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed\/refractory indolent lymphoproliferative malignancies","volume":"108","author":"Gerecitano J.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1294.1294","article-title":"Pre\u2010treatment p27 and bcl\u20106 staining levels correlate with response to bortezomib in non\u2010Hodgkin lymphoma: results from a tissue microarray analysis","volume":"110","author":"Gerecitano J.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.8.2950"},{"key":"e_1_2_6_10_1","article-title":"Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS\u2010341) in patients with indolent lymphomas","volume":"22","author":"O\u2019Connor O.","year":"2003","journal-title":"Proceedings American Society of Clinical Oncology"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_6_12_1","article-title":"Schedule of bortezomib administration may be an important determinant of single\u2010agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)","volume":"25","author":"O\u2019Connor O.","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130781"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034173"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07466.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07466.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:13:51Z","timestamp":1695917631000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07466.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,10]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07466.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07466.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,10]]},"assertion":[{"value":"2009-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}